Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination
Authors:
- 1 June 2009
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (6) , 873-878
Abstract
Objectives: Wegener’s granulomatosis (WG) is a systemic vasculitis characterised by relapsing and remitting disease activity. Immunosuppressive drugs are used to control disease, but increase susceptibility to infection. Therefore, influenza vaccination should be considered in WG patients. This study was performed to assess the immunogenicity of influenza vaccination in WG patients. Methods: A randomised, controlled trial was performed in WG patients with quiescent disease, defined as a Birmingham vasculitis activity score (BVAS) less than 2. Patients were randomly assigned to receive influenza vaccination (n = 49) or to participate as controls (n = 23). In addition, healthy controls (n = 49) were vaccinated. At entry and at 1 and 3–4 months after entry, antibody responses to vaccination were determined. Furthermore, disease activity was measured (BVAS), adverse effects were recorded and antineutrophil cytoplasmic autoantibody (ANCA) titres were determined. Results: WG patients achieved high seroprotection rates to all three influenza strains, comparable with healthy controls. Only the A/H1N1 strain patients had a lower seroconversion rate (p = 0.002) and geometric mean titre (p = 0.037) than controls. After 1 month, one control and one vaccinated WG patient had developed active disease. At 3–4 months, two additional control patients had developed active disease compared with none of the vaccinated patients (p = 0.099). Vaccination did not influence ANCA titres. Adverse effects did not differ between patients and healthy controls. Conclusions: Influenza vaccination in WG patients with quiescent disease induced a sufficient antibody response. Trial registration number: NTR1130.Keywords
This publication has 31 references indexed in Scilit:
- Influenza vaccination of patients with systemic lupus erythematosus: Safety and immunogenecity issuesAutoimmunity Reviews, 2007
- Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive yearsJournal of Medical Virology, 2007
- Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)Arthritis & Rheumatism, 2005
- Annual Revaccination Against Influenza and Mortality Risk in Community-Dwelling Elderly PersonsJAMA, 2004
- Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective studyArthritis & Rheumatism, 2000
- Efficacy of influenza vaccination in adult liver transplant recipientsJournal of Medical Virology, 2000
- Protection Against Influenza After Annually Repeated VaccinationArchives of internal medicine (1960), 1999
- Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trialVaccine, 1994
- HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990–1992Vaccine, 1994
- The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosisArthritis & Rheumatism, 1990